Page 1 | Search Results | Blood | American Society of Hematology

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Early administration of CD20 x CD3 bispecific antibodies 4-6 weeks after CAR-T infusion for patients with residual or progressive large B cell lymphomas

Blood (2025) 146 (Supplement 1): 1952.

https://doi.org/10.1182/blood-2025-1952

Published: 2025

Journal Articles

Impact of broad-spectrum antibiotic exposure on outcomes following autologous stem cell transplantation for patients with relapsed diffuse large B-cell lymphoma or Hodgkin lymphoma

Mary Katherine Anderson, Valerie Shostrom, Robert Bociek, Snegha Ananth, Matthew Lunning, Julie Vose, Christopher D'Angelo

Blood (2025) 146 (Supplement 1): 8021.

https://doi.org/10.1182/blood-2025-8021

Published: 2025

Journal Articles

Frailty markers associated with impaired survival and hospitalization outcomes for patients with aggressive B-cell lymphoma receiving CAR T-cell therapy

Aaron Murray, Valerie Shostrom, Robert Bociek, Snegha Ananth, Julie Vose, Matthew Lunning, Tanya Wildes, Christopher D'Angelo

Blood (2025) 146 (Supplement 1): 785.

https://doi.org/10.1182/blood-2025-785

Published: 2025

Journal Articles

Long Term Outcomes for Patient with Diffuse Large B-Cell (DLBCL) or Hodgkin’s Lymphoma (HL) following Autologous Stem Cell Transplant (ASCT) Who Are Disease Free at Five Years Post Transplant.

Julie M. Vose, MD, Fausto Loberiza, Philip Bierman, Robert Bociek, James Armitage

Blood (2008) 112 (11): 2146.

https://doi.org/10.1182/blood.V112.11.2146.2146

Published: 2008

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Early administration of CD20 x CD3 bispecific antibodies 4-6 weeks after CAR-T infusion for patients with residual or progressive large B cell lymphomas

Impact of broad-spectrum antibiotic exposure on outcomes following autologous stem cell transplantation for patients with relapsed diffuse large B-cell lymphoma or Hodgkin lymphoma

Frailty markers associated with impaired survival and hospitalization outcomes for patients with aggressive B-cell lymphoma receiving CAR T-cell therapy

Long Term Outcomes for Patient with Diffuse Large B-Cell (DLBCL) or Hodgkin’s Lymphoma (HL) following Autologous Stem Cell Transplant (ASCT) Who Are Disease Free at Five Years Post Transplant.

Email alerts

ASH Publications

American Society of Hematology

Update search

Early administration of CD20 x CD3 bispecific antibodies 4-6 weeks after CAR-T infusion for patients with residual or progressive large B cell lymphomas

Impact of broad-spectrum antibiotic exposure on outcomes following autologous stem cell transplantation for patients with relapsed diffuse large B-cell lymphoma or Hodgkin lymphoma

Frailty markers associated with impaired survival and hospitalization outcomes for patients with aggressive B-cell lymphoma receiving CAR T-cell therapy

Long Term Outcomes for Patient with Diffuse Large B-Cell (DLBCL) or Hodgkin’s Lymphoma (HL) following Autologous Stem Cell Transplant (ASCT) Who Are Disease Free at Five Years Post Transplant.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only